Paul Stockdale
Vermogen: 15 964 $ op 31-05-2026
Vermogen: 15 964 $ op 31-05-2026
Paul Stockdale currently works at Oxford BioDynamics Plc, as Chief Financial Officer & Executive Director.
Mr. Stockdale also formerly worked at e-Therapeutics Plc, as Financial Controller from 2012 to 2017 and Deloitte & Touche LLP UK, as Senior Manager from 1996 to 2004.
Mr. Stockdale received his graduate degree from the University of Cambridge.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 10-11-2025 | 6.411.252 ( 0,15% ) | 15 964 $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| OXFORD BIODYNAMICS PLC | Financieel Directeur/CFO | 15-09-2017 |
| Bedrijven | Functie | Einde |
|---|---|---|
| E-THERAPEUTICS PLC | Comptroller/Controller/Auditor | 01-09-2017 |
Deloitte & Touche LLP UK
Deloitte & Touche LLP UK Miscellaneous Commercial ServicesCommercial Services Provides financial advisory and accounting services | Corporate Officer/Principal | 01-01-2004 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 4 |
|---|---|
e-Therapeutics Plc
e-Therapeutics Plc BiotechnologyHealth Technology Discovers and develops drugs | Health Technology |
University of Cambridge
University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Deloitte & Touche LLP UK
Deloitte & Touche LLP UK Miscellaneous Commercial ServicesCommercial Services Provides financial advisory and accounting services | Commercial Services |
Oxford BioDynamics Plc
Oxford BioDynamics Plc BiotechnologyHealth Technology Discovers and develops novel biomarkers | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau